ASK PHARM(SZ:002755)2024-02-01 09:07Group 1: Company Overview - The company is Beijing Aosai Kang Pharmaceutical Co., Ltd. [2] - The investor relations activity took place on January 31, 2024, in the company's conference room [2]. Group 2: 2023 Performance - The company disclosed a forecast indicating a reduction in losses for the year 2023 compared to the previous year [3]. - Detailed data and reasons for performance changes are available in related announcements [3]. Group 3: Product Developments - The newly approved drug, Right Lansoprazole, is a proton pump inhibitor (PPI) with 5-10 times the activity of Left Lansoprazole, showcasing superior pharmacokinetic and pharmacodynamic properties [3]. - The company has been developing Right Lansoprazole since 2014, completing all phases of clinical research [3]. Group 4: Oncology Drug Progress - The innovative anti-tumor drug ASK120067 is under review for a marketing license for second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR T790M mutation [3]. - A Phase III clinical trial for ASK120067 targeting first-line treatment in NSCLC patients has completed enrollment in 2022 and is currently in follow-up [3]. Group 5: Clinical Trials - The Phase III clinical study for ASKB589 aims to enroll 780 patients with CLDN18.2 positive, unresectable locally advanced, recurrent, or metastatic gastric and gastroesophageal junction adenocarcinoma [4]. - The primary endpoint is progression-free survival (PFS) evaluated by an independent review committee, with key secondary endpoints including overall survival (OS) and objective response rate (ORR) [4]. Group 6: New Drug Applications - The company’s new iron supplement, Maltodextrin Iron Capsule, has received FDA and EU approval, demonstrating low adverse reaction rates and high bioavailability [4]. - The antifungal drug Isavuconazole is expected to receive approval in 2024, while Delafloxacin is currently in Phase III clinical trials [4].